Japan's Syphilis Surge, Thirteen-Fold in a Decade, Now Runs Into a Penicillin Shortage

Syphilis cases in Japan have climbed from just over a thousand in 2013 to more than 13,000 in 2025 — a thirteen-fold rise in a country that had the outbreak largely under control a generation ago, and the trend shows no sign of bending. The story has become a fixture of Chinese social media this week, where the outbreak next door is being dissected as a public-health cautionary tale with several unsettling layers.

The demographics first. Men make up about two-thirds of patients, spread across ages from twenties to sixties; infections among women cluster sharply in the twenties, and cases among pregnant women are rising — the pathway by which syphilis damages newborns. Public-health specialists quoted by Japanese and Chinese media converge on the same driver: dating apps have lowered the cost of casual encounters faster than sexual-health services have adapted, while parts of the adult-entertainment industry have moved online, out of reach of the inspections that used to function as a crude safety net.

Then the supply problem. Pfizer, whose penicillin is Japan's first-line syphilis treatment and the only recommended drug for blocking mother-to-child transmission, has had a production failure that will not be fixed until the second half of next year, by the company's own estimate. Japanese clinics are already rationing, and Chinese posters have noted grimly that the shortage will outlast the news cycle.

What has truly transfixed Chinese commentators, though, is a subculture story: reports that some young Japanese people display syphilis symptoms as a fashion. Posts describe people photographing the red rashes of secondary syphilis for social media, faking the rash with makeup — the so-called "syphilis look" (梅毒妆) — and turning infection into a badge of rebelliousness. "When a disease loses its terror, it becomes a costume," one widely shared commentary warned, "and the bill is paid in lifelong health."

Chinese readers are not merely spectators here. Syphilis rates have risen in China too in recent years, and Chinese health educators have spent the week using the Japanese outbreak as a teaching moment about testing and treatment timing — a familiar pattern in which a neighbour's epidemic becomes the hook for domestic health messaging.

The outbreak's course now depends on whether Japan can restock penicillin before the current wave peaks, and whether public-health messaging can compete with the aestheticization of the rash. Both are open questions; the thirteen-fold curve so far suggests the aesthetic is winning.